Yes, elevated total cholesterol, triglycerides, and LDL cholesterol definitively meets the definition of hyperlipidemia—specifically, this pattern represents combined hyperlipidemia (also termed mixed dyslipidemia).
Definition and Classification
This lipid pattern constitutes combined hyperlipidemia, characterized by simultaneous elevations in both cholesterol-containing lipoproteins (LDL) and triglyceride-rich lipoproteins. 1 This is one of the major categories of dyslipidemia, distinct from isolated hypercholesterolemia or isolated hypertriglyceridemia. 1
The term "dyslipidemia" and "hyperlipidemia" are often used interchangeably in clinical practice, though dyslipidemia technically encompasses any lipid abnormality (including low HDL), while hyperlipidemia specifically refers to elevated lipid levels. 2
Clinical Significance of This Pattern
Combined hyperlipidemia represents a particularly high-risk lipid phenotype for cardiovascular disease. 2 This pattern is:
- Extremely common in type 2 diabetes and metabolic syndrome, where it reflects underlying insulin resistance 3, 4
- Associated with small, dense LDL particles that are highly atherogenic, even when absolute LDL-C levels appear only moderately elevated 3
- Linked to increased cardiovascular risk beyond that predicted by LDL-C alone 4
Diagnostic Approach
Lipid levels should be measured after a 9-12 hour fast to accurately assess this pattern. 2 The specific thresholds that define abnormality are:
- LDL cholesterol ≥100 mg/dL (with optimal being <100 mg/dL) 2
- Triglycerides ≥150 mg/dL (with desirable being <150 mg/dL) 2
- Total cholesterol ≥200 mg/dL is generally considered elevated 5
When triglycerides are ≥400 mg/dL, the standard Friedewald equation for calculating LDL-C becomes inaccurate, and either direct LDL-C measurement or β-quantification should be used. 2, 6
Secondary Causes Must Be Excluded
Before labeling this as primary hyperlipidemia, evaluate for secondary causes including: 2
- Uncontrolled diabetes mellitus (check HbA1c, fasting glucose)
- Hypothyroidism (check TSH)
- Chronic kidney disease/nephrotic syndrome (check creatinine, urinalysis for proteinuria)
- Liver disease (check transaminases, alkaline phosphatase)
- Excessive alcohol intake (clinical history)
- Medications: corticosteroids, thiazides, beta-blockers, isotretinoin, cyclosporin, antiretroviral protease inhibitors 2
Treatment Priorities for Combined Hyperlipidemia
The first priority is LDL cholesterol lowering with statin therapy, as this has the strongest evidence base for reducing cardiovascular events. 2 The treatment hierarchy is:
- First-line: High-dose statin therapy to achieve ≥50% LDL-C reduction 2
- Second-line: Statin plus fibric acid derivative (fenofibrate preferred over gemfibrozil due to lower myositis risk when combined with statins) 2
- Third-line: Statin plus ezetimibe if LDL remains elevated despite maximal statin therapy 2
Improved glycemic control is essential as the foundation of triglyceride management, particularly in diabetic patients. 2
Risk Stratification Determines Intensity
For patients with diabetes aged 40-75 years, moderate-to-high intensity statin therapy should be initiated regardless of baseline LDL-C level. 2
For patients with clinical atherosclerotic cardiovascular disease (ASCVD), this combined pattern places them in the "very high-risk" category, warranting LDL-C goals <70 mg/dL with high-intensity statin therapy. 2
Common Pitfall to Avoid
Do not delay statin therapy while attempting lifestyle modifications alone in high-risk patients (those with diabetes, known cardiovascular disease, or LDL-C >200 mg/dL). 2 In these populations, pharmacological therapy should be initiated simultaneously with lifestyle interventions, as the cardiovascular risk is too high to wait 3-6 months for behavioral changes alone.